about
Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.B cell-directed therapies in multiple sclerosis.Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CD19 as a molecular target in CNS autoimmunity.
@ast
CD19 as a molecular target in CNS autoimmunity.
@en
CD19 as a molecular target in CNS autoimmunity.
@nl
type
label
CD19 as a molecular target in CNS autoimmunity.
@ast
CD19 as a molecular target in CNS autoimmunity.
@en
CD19 as a molecular target in CNS autoimmunity.
@nl
prefLabel
CD19 as a molecular target in CNS autoimmunity.
@ast
CD19 as a molecular target in CNS autoimmunity.
@en
CD19 as a molecular target in CNS autoimmunity.
@nl
P2093
P2860
P50
P1476
CD19 as a molecular target in CNS autoimmunity.
@en
P2093
Clemens Warnke
Hans-Christian von Büdingen
Krystin Deason
Martin Stangel
Thomas G Forsthuber
Volker Knappertz
P2860
P2888
P304
P356
10.1007/S00401-014-1313-Z
P577
2014-07-04T00:00:00Z
P6179
1053677182